Share Name Share Symbol Market Type Share ISIN Share Description
Abcam Plc LSE:ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change % Change Share Price Shares Traded Last Trade
  24.00 2.04% 1,202.00 253,221 16:29:58
Bid Price Offer Price High Price Low Price Open Price
1,203.00 1,205.00 1,212.00 1,154.00 1,154.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 260.00 8.40 6.00 200.3 2,752
Last Trade Time Trade Type Trade Size Trade Price Currency
17:58:56 O 12,751 1,199.553 GBX

Abcam (ABC) Latest News

More Abcam News
Abcam Investors    Abcam Takeover Rumours

Abcam (ABC) Discussions and Chat

Abcam Forums and Chat

Date Time Title Posts
16/6/202213:39ABCAM with Charts & News222
19/11/201720:07Investing ? Start with your ABC's703
29/8/201323:08ABCAM - another e-Commerce Retailer120

Add a New Thread

Abcam (ABC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Abcam trades in real-time

Abcam (ABC) Top Chat Posts

Abcam Daily Update: Abcam Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ABC. The last closing price for Abcam was 1,178p.
Abcam Plc has a 4 week average price of 1,083p and a 12 week average price of 1,016p.
The 1 year high share price is 1,760p while the 1 year low share price is currently 1,016p.
There are currently 228,940,916 shares in issue and the average daily traded volume is 215,586 shares. The market capitalisation of Abcam Plc is £2,751,869,810.32.
don carter: Thanks for those valid comments Lord loads & jeffian. I think I had got too attached to ABC, having been in them for a long time and having lived close to Cambridge Science Park, also for a long time. I'm selling my very small residual holding today.
lord loads of lolly: jeffian - totally agreed. I too hold ABC, though it's a fairly small part of my portfolio. I guess I was just trying to offer don carter a possible reason for the recent price falls. When markets get jittery, companies with abnormally high P/Es are especially vulnerable. Investors can lose risk appetite quickly, preferring bombed out "value" stocks to those where future growth has to be taken on trust to justify current valuations. They may not always be proved right, but human nature is what it is!
jeffian: Yes, I too am very wary of very high PER stocks (though I hold some ABC). If you pay a very high multiple of earnings, you are paying today for assumed growth often way into the future, and if such a company stumbles on performance vs. profit projections, it will get hammered. I work on the assumption that, over time, all share valuations will revert to the mean (15x? or whatever) so if I pay more than that, I want pretty good visibility of earnings for the next 2/3 years and won't look beyond that timeframe. However, I wouldn't compare ABC to "the dotcom boom". Many dotcom companies never made a penny piece in their lives, and probably never would, whereas ABC showed absolutely stellar earnings growth from nothing at the outset and although the growth curve may have flattened as the company matures, it's a real business generating real profit.
lord loads of lolly: I also find the 3% markdown in ABC's share price odd, given the higher reported revenues & GM%. Perhaps it's those D&A costs that spooked innvestors? Or the fact the share price had risen quite steeply pre-results, creating a classic case of "buy the rumour, sell the news". Any other ideas?
mayers: Well, some patronising holders may call it noise from the longer term oscillations of the share price but others will see it as a substantial loss shorter term. To many this is a very unpredictable share and I am glad I relinquished it some time ago albeit at some recent loss. On the face of it, it seems bound for 1200p. It is difficult to understand its poor performance in the present climate when support for a subsidiary Avacta has proved profitable for them. Has this exhausted its fragile resources. This is not investment but pure guesswork. I say that despite in the past making reasonable profit.
lord loads of lolly: But if you look at historical share price movement, it’s been a lot less volatile than last week’s.
lord loads of lolly: Abnormal share price volatility here currently. First a 48p (3.39%) drop on 1 June. Then a 56p (4.12%) rise earlier today (3 June) - though most of it evaporated by the close. Can't see anything in June's RNSs to explain it either. Bizarre! Ideas anyone?
bulltradept: The IC has it as a hold Abcam hampered by research shut-downs However, the group has maintained its longer-term targets, while putting the dividend on ice September 14, 2020 By Harriet Clarfelt Antibodies have been a much-discussed topic since the outbreak of Covid-19, playing a central role in testing and treatment programmes. These blood proteins, which develop in response to infection, can show whether a person has already had a disease – helping authorities to monitor the spread of infection. Scientists are also investigating whether antibody therapy can aid patients who are still sick. IC TIP: Hold at 1366p ABC:LSE Abcam PLC 1mth Today change -3.04%Price (GBP) 1,373.00 But the buzz around antibodies and coronavirus forms just one part of a vast global research landscape. And aside from work to target the pandemic, most laboratories were shuttered when lockdowns took hold. Thus, while Abcam (ABC) saw some benefit from the use of its products in virus studies during the 12 months to June, this was tempered by reduced demand elsewhere. The group – which makes and sells protein-research tools, including antibodies, to the life sciences sector – reported revenues of £260m; flat year-on-year, or down 1.4 per cent at constant currencies. Abcam explained that timings “correlated strongly” with the phasing of global government shutdowns. While the first half of the year saw 10.8 per cent sales growth, the second half saw a proportionate decline. However, on a more positive note, the group has not observed any big changes to its underlying customer base. What’s more, management observed that by June 2020, demand was roughly in line with levels seen the previous summer. That recovery goes some way to explain the group’s reiteration of its 2023/24 targets and its associated investment plans. Bosses are aiming for revenues of £450-500m, an adjusted operating margin of more than 30 per cent and a return on capital employed (ROCE) of over 18 per cent. The effects of such an expenditure strategy were evident at the interim mark. When combined with the blow dealt by Covid-19, adjusted costs rose by more than a third to £136m – higher than Peel Hunt’s estimate of £111m. In turn, adjusted operating profits halved to £44.5m, on a margin of 17.1 per cent – down from 32.2 per cent. The broker noted that the “small miss” on costs may have read-across for anticipated expenses in FY2021. The statutory story was rather more dramatic, with pre-tax profits plunging by 85 per cent to £8.4m. This reflected a number of dampeners – the largest of which was the £14.9m write-down of certain technologies tied to Abcam’s acquisition of AxioMx five years ago. Abcam noted that while this is proving commercial feasibility, it has yet to see usage at a scale to support its asset value. Other factors at play included system improvement costs, and spending on the purchase of Expedeon’s proteomics (protein study) and immunology businesses. Meanwhile, in a bid to boost its flexibility around capital allocation, Abcam has put the dividend on ice, with a view to injecting more money into growth opportunities. At the same time, and in the same vein, the group is moving forward with plans to pursue a secondary listing on America’s Nasdaq index. Little wonder, perhaps; more than two-fifths of revenues stem from the US. The improving trends towards the end of Abcam’s fiscal year have continued into the current period, with more labs reopening - and the maintenance of its longer-term growth ambitions is encouraging. Chief executive Alan Hirzel also noted that Covid-19’s broad impact on the immune response has meant that “all kinds of new questions [are] being raised about immunology”. Abcam has accelerated its investments in this research area, “knowing that Covid is likely to spark long-term interest in that field”. Still, for now the crisis continues, and it is impossible to know whether restrictions will be reintroduced – meaning that the group has not offered up full-year guidance. A forward price/earnings multiple of more than 70 times (based on Numis’s projections) keeps us neutral. Last IC view: Hold, 1,143p, 09 Mar 2020
mayers: Looks to be good support at 1400p, otherwise 1200p! Exasperating share however.
buywell3: abc share price imo at bottom support line as i key dyor
Abcam share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220701 17:37:53